Skip to content

RTLC

Active
Private limited companyfounded 2011active for 15 yearsOorlogskruisenlaan 149, 1120 Brussel, Belgium30 active companies are registered at this addressKBO/BCE: BE 0840.135.311
Summary

RTLC has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €66,334 and a net result of -€796. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 66% of 73 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Financials · financial year 2025, micro format

2025 annual accounts filed late (31 days) Filed on 31 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00486482.

Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€796
2024 · €3,736
Working capital
€66,334▼ 84.3%
2024 · €423,530
Trend over the years

2021 to 2025, 5 financial years 2018 to 2025, 8 financial years

The operating result turns negative in 2025: a loss of €465 after €4,924 in 2024, the lowest result in the available series.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result-€465 2025 Net result-€796 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).

Every figure with its change against the financial year before
favourable unfavourable
Line20182019202020212022202320242025
Operating result-€82,333--€33,632▲ 59.2%-€53,975▼ 60.5%€228,543€56,370▼ 75.3%€124,052▲ 120%€4,924▼ 96.0%-€465
Net result-€82,730--€33,663▲ 59.3%-€56,331below the sector's middle half▼ 67.3%€218,044above the sector's middle half€57,245above the sector's middle half▼ 73.7%€123,015above the sector's middle half▲ 115%€3,736within the sector's middle half▼ 97.0%-€796within the sector's middle half
Equity€873,484-€839,820▼ 3.9%€21,489within the sector's middle half▼ 97.4%€239,533within the sector's middle half▲ 1,015%€296,779above the sector's middle half▲ 23.9%€419,794above the sector's middle half▲ 41.5%€423,530above the sector's middle half▲ 0.9%€66,334within the sector's middle half▼ 84.3%
Total assets€884,188-€853,220▼ 3.5%€642,019within the sector's middle half▼ 24.8%€496,815within the sector's middle half▼ 22.6%€297,137within the sector's middle half▼ 40.2%€449,907above the sector's middle half▲ 51.4%€713,855above the sector's middle half▲ 58.7%€107,167within the sector's middle half▼ 85.0%
Debt€10,704-€13,400▲ 25.2%€620,530▲ 4,531%€257,281▼ 58.5%€358▼ 99.9%€30,114▲ 8,300%€290,325▲ 864%€40,834▼ 85.9%
Working capital€873,667-€840,014▼ 3.9%€21,489within the sector's middle half▼ 97.4%€239,533above the sector's middle half▲ 1,015%€296,779above the sector's middle half▲ 23.9%€419,794above the sector's middle half▲ 41.5%€423,530above the sector's middle half▲ 0.9%€66,334within the sector's middle half▼ 84.3%
Solvency98.8%-98.4%▼ 0.4pp3.3%below the sector's middle half▼ 95.1pp48.2%within the sector's middle half▲ 44.9pp99.9%above the sector's middle half▲ 51.7pp93.3%above the sector's middle half▼ 6.6pp59.3%within the sector's middle half▼ 34.0pp61.9%within the sector's middle half▲ 2.6pp
Current ratio84.04-64.61▼ 19.441.03within the sector's middle half▼ 63.571.93within the sector's middle half▲ 0.9014.94above the sector's middle half2.46within the sector's middle half▼ 12.482.62within the sector's middle half▲ 0.17
Return on assets (ROA)-9.4%--3.9%▲ 5.4pp-8.8%below the sector's middle half▼ 4.8pp43.9%above the sector's middle half▲ 52.7pp19.3%above the sector's middle half▼ 24.6pp27.3%above the sector's middle half▲ 8.1pp0.5%within the sector's middle half▼ 26.8pp-0.7%within the sector's middle half▼ 1.3pp
above within below the middle half of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €107,167
Equity €66,334 ▼ 84.3%
Debt €40,834 ▼ 85.9%
Debt's share of the balance-sheet total falls from 40.7% to 38.1%. Equity and debt are lower.
Key figures and ratios
2025 value · change against 2024
Debt to equity
0.62▼
2024 · 0.69
ROE
-1.2%▼
2024 · 0.9%
Debt ≤ 1 year
€40,834▼
2024 · €290,325
Income taxes
€260▼
2024 · €1,041
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 6,910 companies that looked in July 2024 the way this one looks now, 1.1% went bankrupt within 24 months and 90.9% are still going.

  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a small loss
1.1% went bankrupt
7.8% stopped otherwise
90.9% still going

A further 0.2% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,472 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 6,910 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 28 lines
Balance sheet Code20242025
Assets
Total assets20/58€713,855€107,167▼
Current assets29/58€713,855€107,167▼
Amounts receivable within one year40/41€13,371€30,000▲
Trade receivables40€13,371-
Other amounts receivable41-€30,000
Cash at bank and in hand54/58€700,484€77,167▼
Equity and liabilities
Total equity and liabilities10/49€713,855€107,167▼
Equity10/15€423,530€66,334▼
Contributions10/11€712,800€356,400▼
Profit (loss) carried forward14-€289,270-€290,066▼
Amounts payable17/49€290,325€40,834▼
Amounts payable within one year42/48€290,325€40,834▼
Trade debts44€451€400▼
Suppliers440/4€451€400▼
Taxes, remuneration and social security45€6,320€1,302▼
Taxes450/3€6,320€1,302▼
Other amounts payable47/48€283,554€39,132▼
Income statement Code20242025
Other operating charges640/8€387€400▲
Gross operating margin9900€5,311-€66▼
Operating profit (loss)9901€4,924-€465▼
Financial charges65/66B€147€70▼
Recurring financial charges65€147€70▼
Profit (loss) for the period before taxes9903€4,777-€536▼
Income taxes67/77€1,041€260▼
Profit (loss) for the period9904€3,736-€796▼
Profit (loss) for the period to be appropriated9905€3,736-€796▼
Appropriation of the result
Profit (loss) to be appropriated9906-€289,270-€290,066▼
Profit (loss) brought forward from the previous period14P-€293,006-€289,270▲

The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20182019202020212022202320242025Change
Other operating charges640/8---€3,805€3,673€384€387€400▲ 3.2%
Gross operating margin9900-€81,986-€33,285-€52,207€232,348€60,043€124,436€5,311-€66-
Operating profit (loss)9901-€82,333-€33,632-€53,975€228,543€56,370€124,052€4,924-€465-
Financial income75/76B---€2,691€1,491€1,963---
Recurring financial income75€1€284€488€2,691€1,491€1,963---
Financial charges65/66B---€13,189€616€42€147€70▼ 52.1%
Recurring financial charges65€398€315€2,844€13,189€616€42€147€70▼ 52.1%
Profit (loss) for the period before taxes9903-€82,730-€33,663-€56,331€218,044€57,245€125,973€4,777-€536-
Income taxes67/77-----€2,958€1,041€260▼ 75.0%
Profit (loss) for the period9904-€82,730-€33,663-€56,331€218,044€57,245€123,015€3,736-€796-
Profit (loss) for the period to be appropriated9905-€82,730-€33,663-€56,331€218,044€57,245€123,015€3,736-€796-
Line20182019202020212022202320242025Change
Assets
Total assets20/58€0.9m€0.9m€0.6m€0.5m€0.3m€0.4m€0.7m€0.1m▼ 85.0%
Current assets29/58€0.9m€0.9m€0.6m€0.5m€0.3m€0.4m€0.7m€0.1m▼ 85.0%
Stocks and contracts in progress3--€0.6m------
Amounts receivable within one year40/41€0.02m€0.01m€0.07m€0.1m€0.2m€0.2m€0.01m€0.03m▲ 124%
Trade receivables40---€0.07m€0.1m€0.2m€0.01m--
Other amounts receivable41---€0.05m€0.05m€0.05m-€0.03m-
Cash at bank and in hand54/58€0.9m€0.8m€0.01m€0.4m€0.1m€0.2m€0.7m€0.08m▼ 89.0%
Deferred charges and accrued income490/1---€0.01m€0.01m----
Equity and liabilities
Total equity and liabilities10/49€0.9m€0.9m€0.6m€0.5m€0.3m€0.4m€0.7m€0.1m▼ 85.0%
Equity10/15€0.9m€0.8m€0.02m€0.2m€0.3m€0.4m€0.4m€0.07m▼ 84.3%
Contributions10/11€1.5m€1.5m-€0.7m€0.7m€0.7m€0.7m€0.4m▼ 50.0%
Profit (loss) carried forward14-€0.6m-€0.6m-€0.7m-€0.5m-€0.4m-€0.3m-€0.3m-€0.3m▼ 0.3%
Amounts payable17/49€0.01m€0.01m€0.6m€0.3m€358€0.03m€0.3m€0.04m▼ 85.9%
Amounts payable within one year42/48€0.01m€0.01m€0.6m€0.3m€358€0.03m€0.3m€0.04m▼ 85.9%
Trade debts44€0.01m€0.01m€0.004m€0.003m€358€448€451€400▼ 11.4%
Suppliers440/4---€0.003m€358€448€451€400▼ 11.4%
Taxes, remuneration and social security45-----€0.03m€0.006m€0.001m▼ 79.4%
Taxes450/3-----€0.03m€0.006m€0.001m▼ 79.4%
Other amounts payable47/48---€0.3m-€0.001m€0.3m€0.04m▼ 86.2%
Line20182019202020212022202320242025Change
Profit (loss) for the period9904-€82,730-€33,663-€56,331€218,044€57,245€123,015€3,736-€796-
Operating cash flow (approximation)-€82,730-€33,663-€56,331€218,044€57,245€123,015€3,736-€796-
Change in cash--€25,031-€830,362€352,410-€252,387€104,655€482,945-€623,317-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 14 filings with the National Bank
Financial year Type Filed Reference
31-12-2025 micro format 31-08-2026 2026-00486482
31-12-2024 micro format 31-08-2025 2025-00473741
31-12-2023 micro format 29-08-2024 2024-00437860
31-12-2022 micro format 01-09-2023 2023-00436101
31-12-2021 micro format 05-08-2022 2022-20278665
31-12-2020 micro format 11-06-2021 2021-19500238
31-12-2019 full format 31-07-2020 2020-38200281
31-12-2018 micro format 26-07-2019 2019-39400312
31-12-2017 micro format 31-08-2018 2018-61000337
31-12-2016 micro format 31-07-2017 2017-39600170

Show all 14 filings

Similar companies · same sector, comparable size

Of the 148 active companies whose main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201), figures are known for 119. 34 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.